Cesca Therapeutics Inc(NASDAQ:KOOL) announced the earnings results for Fiscal Year 2017 and Q2. The results came in during After-Market on Feb 13, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Earnings per share were $-0.34.
Cesca Therapeutics Inc (KOOL) remained unchanged at the close of Wednesday session. Even as the volume increased to 27,081 ,the shares failed to make any impression and ended at -0.0001 points or 0.00% at $2.9499. The trading session commenced at $2.95 and the stock hit a high of $2.99 and touched $2.93 at the lower end. Considering that the stock pared all of the losses, it can be said as a positive sign. The share price has a 52-week high of $7.39 and the 52-week low is $1.8501. The company has a market cap of $29 M and has approximately 98,86,402 outstanding shares.
Several Insider Transactions has been reported to the SEC. On Dec 28, 2016, (hong Kong) Ltd Boyalife (10% owner) purchased 6,102,942 shares at $2.52 per share price.Also, On Sep 4, 2015, Matthew T Plavan (Former CEO) sold 17,271 shares at $0.68 per share price.
Cesca Therapeutics Inc. is focused on the research development and commercialization of autologous cell-based therapeutics for use in regenerative medicine. The Company is engaged in developing and manufacturing automated blood and bone marrow processing systems that enable the separation processing and preservation of cell and tissue therapy products. It focuses in three target markets to serve patients physicians and partners: cellular therapeutics medical/diagnostic device development and commercialization and cell manufacturing and banking. The Company focuses on three areas: critical limb ischemia (CLI) acute myocardial infarction (AMI) and bone marrow transplant (BMT). The Company offers SurgWerks and VXP System Platform and CellWerks Platform. Its products include AutoXpress (AXP) System MarrowXpress (MXP) System BioArchive System and Res-Q 60 BMC. It also provides cell manufacturing and banking services.